Objectives: As part of a search for new therapeutic opportunities to treat chagasic patients, in vitro efficacy studies were performed to characterize the activity of five novel arylimidamides (AIAs) against Trypanosoma cruzi.
Introduction
Chagas' disease (CD) is a neglected disease of poor, rural and forgotten populations, representing one of the main public health problems in 22 developing countries of Latin America. 1 Nifurtimox and benznidazole are recommended for all acute, early chronic and reactivated cases, but produce variable results mostly related to the endemic area. Both exhibit considerable undesirable side effects, are administered over 30 or more days and are not very effective against the late chronic phase. 2, 3 Another challenge is blood prophylaxis in endemic areas, since the only trypanosomicidal agent (gentian violet) has toxicity problems, gives the blood a purple colour and may stain the skin and mucosa of recipients. 4 In vitro and in vivo studies have shown the promising efficacy of diamidines and congeners, mainly arylimidamides (AIAs), against Trypanosoma cruzi.
2, 5, 6 Because recent findings also reported the pharmacological properties and biological efficacy of AIAs, such as DB745, against Leishmania in models of in vitro and in vivo infection, 7 in this study the trypanocidal activity of five novel AIAs was evaluated in vitro against different strains of T. cruzi.
Methods

Drugs
All amidines (see Figure S1 ; available as Supplementary data at JAC Online) were synthesized according to published procedures. 8 Benznidazole (LAFEPE, Brazil) and gentian violet (Sigma-Aldrich) were used as previously reported. 5 
Cardiac cell cultures and cytotoxicity assays
To rule out toxic effects against mammalian cells, uninfected primary cultures of embryonic cardiomyocytes (CMs) were incubated at 378C for 24 and 72 h and LC 50 values were determined by MTT colorimetric assays. 
Parasites
Different strains of T. cruzi were used (see Table S1 ; available as Supplementary data at JAC Online). Bloodstream trypomastigotes (BTs) were obtained from Swiss mice infected with T. cruzi.
6 Intracellular amastigotes lodged within CMs were employed as reported previously. 6 
Antitrypanosomal activity
BTs were incubated with compounds (0-32 mM) for 24 h at 378C or were treated for 5 -60 min with 0.1-10 mg/mL DB766, DB745B, DB709 and the diamidine DB569. 6 To identify a possible candidate for blood bank prophylaxis, BTs were maintained at 48C for 24 h in freshly isolated mouse blood (96% and 50%) in the presence or absence of serial dilutions of the compound (up to 32 mM). 5 The parasite death rates were determined through direct analysis by light microscopy, allowing the calculation of IC 50 values. 5 For the analysis on intracellular parasites, after 24 h of infection using BTs (ratio 10:1), infected CMs were incubated for 72 h with the compounds (0 -10.6 mM) and the number of released parasites quantified for determination of IC 50 values. 2 All procedures were carried out in accordance with the guidelines approved by Fiocruz CEUA 0099/01. Statistical analysis was carried out using analysis of variance (ANOVA), with the level of significance set at P≤ 0.05.
Results
DB667, DB709, DB745B, DB749 and DB946 gave a dosedependent trypanocidal effect against BTs (Y strain) (see Figure S2 ; available as Supplementary data at JAC Online). DB709, DB749 and DB946 presented IC 50 values of 0.09+0.03, 2.5+0.73 and 0.05+0.002 mM, respectively. DB745B was the most effective, showing an IC 50 value of 0.015+0.002 mM (Table 1) .
To compare the efficacy of DB745B with other AIAs previously studied (DB766) 5 and with a well-known trypanocidal diamidine (DB569), 6 BTs were incubated for 15 min with different concentrations of each compound (0.1 -10 mg/mL). The lower concentrations revealed large differences between the activities of DB745B and DB766; 78% and 27% parasite death, respectively, with 1 mg/mL (data not shown). To further explore the efficacies of these compounds, a time -kill study was conducted using the higher concentration (10 mg/mL). After 5 min a statistically significant difference was found between DB745B and DB766 (P ¼ 0.009); DB745B induced 51% parasite lysis, whereas DB569 and DB766 induced only 16% and 27% parasite lysis, respectively ( Figure S2a ). After 60 min both AIAs induced more than 96% parasite lysis, whereas DB569 produced about 50% ( Figure S2b) .
When assayed at 48C using 96% mouse blood, DB745B presented the highest activity, exhibiting IC 50 ¼0.66+0.25 mM. DB667, DB709 and DB749 gave IC 50 values .32 mM, while DB946 showed modest activity (IC 50 ¼ 22 mM) ( Figure S2c) . DB745B was also assayed against other strains with different patterns of natural resistance to benznidazole and nifurtimox (Table S1) . 5 For comparative purposes we also included the diamidine DB75, which displays only modest activity against T. cruzi. 6 Although no effect was found for both DB75 and DB749 (IC 50 ≥31 mM), DB745B showed significant activity, regardless of the drug resistance parasite phenotype, giving IC 50 values ranging from 0.3 to 0.7 mM, and greater efficacy than gentian violet (Table 2 ). DB745B and DB667 tested against a broader panel of T. cruzi strains (855, 875, MS1523 and RBVIII) showed that although both were more active than benznidazole, DB667 was less active than DB745B (data not shown).
The five novel AIAs did not cause significant loss of cardiac cell viability after treatment for 24 and 72 h, displaying LC 50 values ≥32 and 10.6 mM, respectively (data not shown). The incubation of T. cruzi-infected CMs with non-toxic concentrations of AIAs (≤3.5 mM) resulted in strong inhibition of parasite burden, presenting a dose-dependent and greater activity than benznidazole ( Figure S2d and Table 1 ).
Regarding selectivity indexes (SIs), except for DB749, all the other AIAs displayed high SIs against BTs and intracellular parasites, ranging from 352 to 2133 and 53 to 530, respectively (Table 1) .
Discussion
A systematic lead discovery programme performed by the Consortium for Parasitic Drug Development (http://www.thecpdd. org/) demonstrated that novel AIAs such as DB745B and The activity of the compounds against bloodstream trypomastigotes (BTs) and intracellular parasites was evaluated during their incubation at 48C (as indicated) or otherwise at 378C for 24 h and 72 h.
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DB766 are effective against Leishmania infection in vitro and in vivo, do not exhibit mutagenicity, display low acute toxicity, have moderate oral bioavailability, are distributed to different tissues such as the liver and spleen, present large volumes of distribution and have an elimination half-life ranging from 1 to 2 days in mice. 7 As DB766 also presented potent anti-T. cruzi activity, 5 we screened for the trypanocidal effect of five novel AIAs, including DB745B. All AIAs exhibited considerable activity against T. cruzi, but DB745B was the most active, even in the presence of blood constituents. The loss of activity exhibited by DB667, DB709, DB749 and DB946 may be related to their association with and/or inactivation by serum components, as reported previously. 2 The efficacy of DB745B in the presence of blood is a desirable characteristic shared by a few other AIAs, such as DB766, 5 that was noted during the evaluation of new trypanocidal agents for use in blood banks. Although the transfusion procedures that have been implemented have reduced the number of bloodrelated new infections, these procedures are not universally followed. Also, the only trypanocidal agent available for chemical prophylaxis of blood in areas of high endemicity is gentian violet, which is a toxic cationic dye that has several limitations. 1 As recommended for drug screening against CD, 9 a promising agent should: (i) be active against bloodstream and intracellular forms; (ii) be active against a large panel of parasite isolates, including those that express natural resistance to benznidazole and nifurtimox; (iii) present efficacy equal to or better than the reference drugs; and (iv) display a high SI (≥50). In this study, all these requirements were fulfilled, especially by DB745B. All AIAs were more active than benznidazole (e.g. DB745B is about 860 and 90 times more effective against BTs and intracellular parasites, respectively). DB745B is effective against a large panel of strains (855, 875, MS1523 and RBVIII strains are present in peridomiciliary and sylvatic ecotopes), including those that express natural resistance to benznidazole, 10 and is more active than the diamidines DB569 and DB75, confirming previous studies that revealed the superior activity of AIAs compared with diamidines against T. cruzi.
2,6 Dose-dependent and timepoint studies demonstrated that DB745B is faster acting than DB766, requiring further studies to explore the possibility that different transport mechanisms and/or cellular targets may be operating. Our findings warrant additional in vivo studies with DB745B using acute and chronic experimental models of T. cruzi infection with the goal of identifying novel lead AIA candidates against this parasite. The activity of the compounds against BTs was evaluated for 24 h during their incubation at 48C with 50% mouse blood.
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